CRISPR QC

04/20/2022

We’re going to be at
April 28th • Petco Park
hosts San Diego's Innovation Day celebration. Come check out our booth
and chat with one of the members from our team. Enjoy the richness of diversity with arts and
cultural installations throughout the event.
Learn More ➡️

FIRST ANNUAL San Diego Innovation Day Thursday | April 28 4 pm – 8 pm Connect is leading a takeover at Petco Park, open to the public from 4-8pm. Check out more than one hundred life science and technology companies exhibiting, local artists, cultural installations, and fireworks (at 8pm) to celeb...

04/05/2022

Thank you Cardea Bio for launching CRISPR QC to bring to market CRISPR quality control services to improve gene editing. With BPU™ (Biosignal Process Unit) Platform and CRISPR-CHIP™ we look forward to helping organizations reach their highest potential.

“One of the challenges for successful CRISPR gene editing is a lack of understanding and standardization of processes around predicting and optimizing CRISPR assay outcomes. At CRISPR QC, we work with scientists to improve the quality of life for all. That's why we're excited to work with the Chief Scientific Officer of Cardea Bio, Dr. Kiana Aran, who recently received NIH funding to help set some of the US quality control standards for CRISPR therapies,” states Ross Bundy, President of CRISPR QC.

CRISPR QC focuses on bringing insightful data to scientists in the CRISPR space with our first commercially available solution CRISPR-Complete™, available now.

02/03/2022

Congratulations to Chief Science Officer of Cardea Bio Dr. Kiana Aran for receiving NIH funding to help set quality control standards for CRISPR therapies. One of the challenges for successful CRISPR gene editing is a lack of understanding and standardization of processes around predicting and optimizing CRISPR assay outcomes. At CRISPR QC, we work with scientists to improve the quality of life for all. Like Dr. Kiana Aran, CRISPR QC is at the forefront of CRISPR quality control. We welcome her leadership and look forward to implementing her guidance in providing safe and predictable CRISPR outcomes.

KGI's Dr. Kiana Aran was selected for a grant from the NIH to develop CRISPR Quality Control standards for therapeutics applications.